Bexagliflozin found as effective as dapagliflozin for glycemic control in diabetes: Study Written By Medha Baranwal11 April 2024 9:30 AM ISTChina: A 24-week, phase 3 trial has shed light on the safety and efficacy of bexagliflozin versus dapagliflozin as an adjunct to metformin in Chinese...
SGLT2 inhibitors may protect T2D patients with AF from HF and renal complications: Study Written By Jacinthlyn Sylvia9 April 2024 10:00 AM ISTA recent study found a significant discovery in the treatment of patients with from type 2 diabetes (T2D) with concurrent atrial fibrillation (AF)...
Role of SGLT2 inhibitors beyond diabetes care to metabolic care: Indian Perspective Written By Medha Baranwal3 April 2024 9:00 PM ISTIndia: A recent article published in the Indian Journal of Endocrinology and Metabolism has presented an Indian perspective on the paradigm shift of...
Advancing therapy with iGlarLixi safe and effective for diabetes treatment irrespective of SGLT2 inhibitors use: Study Written By Medha Baranwal3 April 2024 2:15 AM ISTA patient-level pooled analysis of three randomized clinical trials (RCTs) revealed improvement in glycemic status without increased risk of...
SGLT2 Inhibitors Improve Skeletal Muscle Pathology in Heart Failure, reveals study Written By Dr Riya Dave1 April 2024 7:45 PM ISTPatients with heart failure and reduced ejection fraction (HFrEF) often experience skeletal muscle pathology, contributing to symptoms and reduced...
SGLT2 inhibitors clinically beneficial in patients with gout, suggests review Written By Medha Baranwal29 March 2024 6:45 PM ISTUSA: Sodium-glucose cotransporter type 2 (SGLT2) inhibitors may provide improved outcomes in treating gout and its common comorbidities, a recent...
EVERGREEN Webinar: Clinical FAQs on T2DM Care, Addressed by Dr V Mohan Written By Dr Jeegar Dattani6 March 2024 12:29 PM ISTThe Evergreen webinar addressed the clinical applicability of Linagliptin and Dapagliflozin in real-world clinical scenarios of type 2 diabetes....
Canagliflozin improves diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns: Study Written By Medha Baranwal22 Feb 2024 6:00 AM ISTChina: Canagliflozin (CANA) regulates metabolic reprogramming in diabetic kidney disease (DKD) by inducing fasting-like and aestivation-like metabolic...
SGLT2 inhibitors preferred oral antidiabetic for individuals with both NAFLD and T2D,reveals study Written By Dr Riya Dave15 Feb 2024 9:30 AM ISTNonalcoholic fatty liver disease (NAFLD) is prevalent among individuals with type 2 diabetes (T2D) and presents a significant health burden. While...
Diabetes patients taking SGLT2 inhibitors may exhibit false positive urine ethanol tests: NEJM Written By Medha Baranwal9 Feb 2024 11:15 AM ISTUSA: A recent article published in the New England Journal of Medicine described a patient with diabetes who was taking empagliflozin, an SGLT2...
Earlier treatment with SGLT2 inhibitor canagliflozin confers cardiorenal benefits in type 2 diabetes Written By Medha Baranwal7 Feb 2024 10:00 AM ISTCanada: A pooled analysis of the CANVAS Program and CREDENCE trials showed that earlier treatment with canagliflozin confers consistent cardiorenal...
Medical Bulletin 03/February/2024 Anshika Mishra3 Feb 2024 3:00 PM ISTHere are the top medical news of the day:Age-Related Brain Changes and Pain Sensitivity: Impact on Older WomenA new study has found that the brain...
